HY-103636 Search Results


protac brd9 degrader-1  (MedChemExpress)
93
MedChemExpress protac brd9 degrader-1
Protac Brd9 Degrader 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protac brd9 degrader-1/product/MedChemExpress
Average 93 stars, based on 1 article reviews
protac brd9 degrader-1 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
protac bet degrader 1  (MedChemExpress)
93
MedChemExpress protac bet degrader 1
Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET <t>Degrader-1,</t> and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.
Protac Bet Degrader 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protac bet degrader 1/product/MedChemExpress
Average 93 stars, based on 1 article reviews
protac bet degrader 1 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
dfkbp-1  (MedChemExpress)
93
MedChemExpress dfkbp-1
Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET <t>Degrader-1,</t> and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.
Dfkbp 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dfkbp-1/product/MedChemExpress
Average 93 stars, based on 1 article reviews
dfkbp-1 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
3-methoxytyramine  (MedChemExpress)
94
MedChemExpress 3-methoxytyramine
Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET <t>Degrader-1,</t> and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.
3 Methoxytyramine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3-methoxytyramine/product/MedChemExpress
Average 94 stars, based on 1 article reviews
3-methoxytyramine - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
protac sirt2 degrader-1  (MedChemExpress)
N/A
PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2
   Buy from Supplier

Image Search Results


Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET Degrader-1, and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.

Journal: ACS Pharmacology & Translational Science

Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

doi: 10.1021/acsptsci.1c00032

Figure Lengend Snippet: Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET Degrader-1, and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.

Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

Techniques:

TR-FRET dose–response curves of PROTAC ternary complex formation. The compounds tested include dBET1, PROTAC BET Degrader-1, PROATC BET Degrader-2, (+)-JQ1, HJB97, thalidomide, and lenalidomide. The assays were performed under condition 5 with a 180 min incubation with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM). (a) Relative TR-FRET signals in RTU (10 000 × 520 nm/490 nm). (b) Normalized TR-FRET signals as fold change to DMSO.

Journal: ACS Pharmacology & Translational Science

Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

doi: 10.1021/acsptsci.1c00032

Figure Lengend Snippet: TR-FRET dose–response curves of PROTAC ternary complex formation. The compounds tested include dBET1, PROTAC BET Degrader-1, PROATC BET Degrader-2, (+)-JQ1, HJB97, thalidomide, and lenalidomide. The assays were performed under condition 5 with a 180 min incubation with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM). (a) Relative TR-FRET signals in RTU (10 000 × 520 nm/490 nm). (b) Normalized TR-FRET signals as fold change to DMSO.

Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

Techniques: Incubation

Dose–response curves of competing compounds in the TR-FRET GST-BRD2(BD1)/PROTAC BET Degrader 1/His-CRBN(DDB1) ternary complex formation assay. The compounds tested included (+)-JQ1, HJB97, thalidomide, lenalidomide, RVX-208, and VH032. PROTAC BET Degrader 1 (4.1 nM) was used under condition 5 with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) with a 180 min incubation.

Journal: ACS Pharmacology & Translational Science

Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

doi: 10.1021/acsptsci.1c00032

Figure Lengend Snippet: Dose–response curves of competing compounds in the TR-FRET GST-BRD2(BD1)/PROTAC BET Degrader 1/His-CRBN(DDB1) ternary complex formation assay. The compounds tested included (+)-JQ1, HJB97, thalidomide, lenalidomide, RVX-208, and VH032. PROTAC BET Degrader 1 (4.1 nM) was used under condition 5 with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) with a 180 min incubation.

Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

Techniques: Tube Formation Assay, Incubation

DMSO tolerance test of the PROTAC BET Degrader-1 TR-FRET ternary complex formation assay. Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) were used with a 180 min incubation. (a) Relative TR-FRET signals (10 000 × 520 nm/490 nm, RTU). (b) Normalized TR-FRET signals (as fold change to DMSO). TR-FRET signals from the DMSO control are displayed to the left of the curves.

Journal: ACS Pharmacology & Translational Science

Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

doi: 10.1021/acsptsci.1c00032

Figure Lengend Snippet: DMSO tolerance test of the PROTAC BET Degrader-1 TR-FRET ternary complex formation assay. Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) were used with a 180 min incubation. (a) Relative TR-FRET signals (10 000 × 520 nm/490 nm, RTU). (b) Normalized TR-FRET signals (as fold change to DMSO). TR-FRET signals from the DMSO control are displayed to the left of the curves.

Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

Techniques: Tube Formation Assay, Incubation

Comparison of PROTAC BET Degrader-1, PROTAC BET Degrader-2, and dBET1 for their Previously Reported IC 50 Values and TR-FRET Maximal PROTAC Efficacy Concentrations

Journal: ACS Pharmacology & Translational Science

Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

doi: 10.1021/acsptsci.1c00032

Figure Lengend Snippet: Comparison of PROTAC BET Degrader-1, PROTAC BET Degrader-2, and dBET1 for their Previously Reported IC 50 Values and TR-FRET Maximal PROTAC Efficacy Concentrations

Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

Techniques: Comparison, Inhibition, Concentration Assay

Effect of DMSO Concentration on the Peak Relative TR-FRET Signal and the Corresponding Maximal PROTAC Efficacy Concentration for PROTAC BET Degrader-1 in the TR-FRET Complex Formation Assay

Journal: ACS Pharmacology & Translational Science

Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

doi: 10.1021/acsptsci.1c00032

Figure Lengend Snippet: Effect of DMSO Concentration on the Peak Relative TR-FRET Signal and the Corresponding Maximal PROTAC Efficacy Concentration for PROTAC BET Degrader-1 in the TR-FRET Complex Formation Assay

Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

Techniques: Concentration Assay